Gilead, Janssen expand HIV combo R&D deals
This article was originally published in Scrip
Executive Summary
Gilead Sciences and Johnson & Johnson subsidiary Janssen R&D Ireland have agreed to expand a 2009 development and commercialization deal to pursue a new once-daily single tablet containing tenofovir alafenamide (TAF), emtricitabine and rilpivirine to treat HIV.